CN107949383B - 用于成像的含氮氧化合物的淀粉样蛋白结合剂 - Google Patents

用于成像的含氮氧化合物的淀粉样蛋白结合剂 Download PDF

Info

Publication number
CN107949383B
CN107949383B CN201680048440.1A CN201680048440A CN107949383B CN 107949383 B CN107949383 B CN 107949383B CN 201680048440 A CN201680048440 A CN 201680048440A CN 107949383 B CN107949383 B CN 107949383B
Authority
CN
China
Prior art keywords
compound
amyloid
compounds
slf
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680048440.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107949383A (zh
Inventor
J·沃斯
刘瑞武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN107949383A publication Critical patent/CN107949383A/zh
Application granted granted Critical
Publication of CN107949383B publication Critical patent/CN107949383B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/20—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations containing free radicals, e.g. trityl radical for overhauser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680048440.1A 2015-08-18 2016-08-17 用于成像的含氮氧化合物的淀粉样蛋白结合剂 Active CN107949383B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562206706P 2015-08-18 2015-08-18
US62/206,706 2015-08-18
PCT/US2016/047414 WO2017031239A1 (en) 2015-08-18 2016-08-17 Nitroxide containing amyloid binding agents for imaging and therapeutic uses

Publications (2)

Publication Number Publication Date
CN107949383A CN107949383A (zh) 2018-04-20
CN107949383B true CN107949383B (zh) 2022-08-23

Family

ID=58051663

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680048440.1A Active CN107949383B (zh) 2015-08-18 2016-08-17 用于成像的含氮氧化合物的淀粉样蛋白结合剂

Country Status (8)

Country Link
US (3) US10478513B2 (enExample)
EP (1) EP3337475B1 (enExample)
JP (1) JP7114074B2 (enExample)
KR (1) KR20180052611A (enExample)
CN (1) CN107949383B (enExample)
AU (2) AU2016308189B2 (enExample)
CA (1) CA2994178C (enExample)
WO (1) WO2017031239A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478513B2 (en) * 2015-08-18 2019-11-19 The Regents Of The University Of Califonia Nitroxide containing amyloid binding agents for imaging and therapeutic uses
CN108600272B (zh) 2018-05-10 2020-08-04 阿里巴巴集团控股有限公司 一种区块链数据处理方法、装置、处理设备及系统
CN110152009A (zh) * 2019-05-09 2019-08-23 中国科学院兰州化学物理研究所 一种多取代白藜芦醇自旋标记衍生物及其制备方法和应用
KR102344676B1 (ko) * 2020-02-12 2021-12-30 한국과학기술연구원 타우 응집체에 선택적으로 결합하는 근적외선 형광 탐침자로서 유효한 신규 화합물 및 이의 제조방법
PL441664A1 (pl) * 2022-07-07 2024-01-08 Uniwersytet Warszawski Nitroksylowa pochodna polifenolu, sposoby jej wytwarzania oraz jej zastosowanie

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360731A (zh) * 2005-10-11 2009-02-04 匹兹堡大学 作为淀粉样发生蛋白成像剂的同位素标记苯并呋喃化合物
US20090123369A1 (en) * 2006-03-30 2009-05-14 The Trustees Of The University Of Pennsylvania Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques
US20090162283A1 (en) * 2005-11-30 2009-06-25 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
US20110071301A1 (en) * 2007-11-02 2011-03-24 The Regents Of The University Of California Abeta-binding small molecules
CN102973954A (zh) * 2004-07-02 2013-03-20 匹兹堡大学高等教育联邦体系 淀粉样蛋白成像作为抗淀粉样蛋白疗法的功效的替代标记物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1208697A (en) * 1995-12-28 1997-07-28 Daiichi Radioisotope Laboratories, Ltd. Diagnostic drugs
US6949575B2 (en) * 2000-05-04 2005-09-27 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
JP2004067659A (ja) * 2002-06-12 2004-03-04 Bf Kenkyusho:Kk タウ蛋白蓄積性疾患の診断プローブとしてのベンゾイミダゾール環含有化合物
TW200813035A (en) * 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
BRPI0919079B1 (pt) * 2008-09-23 2022-02-15 Wista Laboratories Ltd Métodos para marcar filamentos helicoidais pareados (phfs), e para marcar tau agregado, bem como compostos ligantes para moléculas tau agregadas
JP5825608B2 (ja) * 2010-08-06 2015-12-02 国立大学法人京都大学 ピリジルベンゾフラン誘導体
WO2013112605A2 (en) 2012-01-23 2013-08-01 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
EP4335505A3 (en) 2012-11-30 2024-06-05 The Regents of The University of California Anticonvulsant activity of steroids
US10478513B2 (en) * 2015-08-18 2019-11-19 The Regents Of The University Of Califonia Nitroxide containing amyloid binding agents for imaging and therapeutic uses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102973954A (zh) * 2004-07-02 2013-03-20 匹兹堡大学高等教育联邦体系 淀粉样蛋白成像作为抗淀粉样蛋白疗法的功效的替代标记物
CN101360731A (zh) * 2005-10-11 2009-02-04 匹兹堡大学 作为淀粉样发生蛋白成像剂的同位素标记苯并呋喃化合物
US20090162283A1 (en) * 2005-11-30 2009-06-25 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
US20090123369A1 (en) * 2006-03-30 2009-05-14 The Trustees Of The University Of Pennsylvania Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques
US20110071301A1 (en) * 2007-11-02 2011-03-24 The Regents Of The University Of California Abeta-binding small molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Binding Mechanism and Magnetic Properties of a Multifunctional Spin Label for Targeted EPR Imaging of Amyloid Proteins:Insight from Atomistic Simulations and First-Principles Calculations;Xin Li et al;《Journal of chemical theory and computation:JCTC》;20121023;第8卷(第11期);4766-4774 *
Monitoring the aggregation processes of amyloid-beta using a spin-labeled,fluorescent nitroxyl radical;Fumiya Mito et al.;《Chemical Communications》;20110101;第47卷(第17期);5070-5072 *
Novel Styrylpyridines as Probes for SPECT Imaging of Amyloid Plaques;Wenchao Qu et al.;《Journal of Medicinal Chemistry》;20070501;第50卷(第9期);2157-2165 *
Synthesis and biological evaluation of (E)-3-styrylpyridine derivatives as amyloid imaging agents for Alzheimer"s disease;ONO M ET AL.;《NUCLEAR MEDICINE AND BIOLOGY》;20050501;第32卷(第4期);329-335 *

Also Published As

Publication number Publication date
AU2016308189A1 (en) 2018-02-22
CA2994178C (en) 2024-03-19
US10881748B2 (en) 2021-01-05
WO2017031239A1 (en) 2017-02-23
CA2994178A1 (en) 2017-02-23
US10478513B2 (en) 2019-11-19
CN107949383A (zh) 2018-04-20
US20200246492A1 (en) 2020-08-06
AU2016308189B2 (en) 2021-03-11
AU2021203794A1 (en) 2021-07-08
EP3337475A1 (en) 2018-06-27
EP3337475A4 (en) 2019-04-10
US20180221514A1 (en) 2018-08-09
HK1257493A1 (en) 2019-10-25
US20220202962A1 (en) 2022-06-30
JP2018523657A (ja) 2018-08-23
JP7114074B2 (ja) 2022-08-08
KR20180052611A (ko) 2018-05-18
EP3337475B1 (en) 2024-10-02
US12064488B2 (en) 2024-08-20

Similar Documents

Publication Publication Date Title
US12064488B2 (en) Nitroxide containing amyloid binding agents for imaging and therapeutic uses
US10149644B2 (en) Curcumin derivatives for amyloid-β plaque imaging
EP3119761B1 (en) Amyloid targeting agents and methods of using the same
JP5897461B2 (ja) ミエリン塩基性タンパク質のイメージング
US9422286B2 (en) Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease
WO2005016888A1 (ja) アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
US12551576B2 (en) Chemiluminescent probes
US8617515B2 (en) Imaging of myelin basic protein
US20210252170A1 (en) Targeted contrast agents for mri of alpha-synuclein deposition
KR101101977B1 (ko) 2-아릴나프탈렌, 2-아릴퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
CN108290883B (zh) 用于tau成像的氮杂环丁烷衍生物
HK1257493B (en) Nitroxide containing amyloid binding agents for imaging and therapeutic uses
US11779664B2 (en) Targeted contrast agents for MRI of alpha-synuclein deposition
EP4368622A1 (en) Method of purifying a compound
AU2010256533B2 (en) Imaging of myelin basic protein
HK1257042B (en) Azetidine derivatives for tau imaging

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant